Scientists Finally Uncover Why Ozempic Stops Working for Some People

NIH researchers found in mice that semaglutide’s weight-loss effect depends on cAMP signaling in specific hindbrain neurons.

Blocking PDE4 with roflumilast extended that signal in more cells, suggesting a way to prolong GLP-1 drug effects.

The work may help explain why drugs like Ozempic work better for some people and why weight loss can plateau over time.

If confirmed in humans, the findings could point to ways to make GLP-1 treatments last longer or reduce fading response.